Backed by CHPA member companies Kenvue and Colgate-Palmolive, and developed in collaboration with The Skin Cancer Foundation and the American Dental Association (ADA), the programs will reach more than 1.2 million students nationwide during the back-to-school season.
Each year, CHPA’s RSQ Conference unites industry, regulators, and academia to focus on the evolving self-care sector.
"The passage of HB 3087 represents a significant victory for both consumer access and public safety,” said Carlos Gutierrez, vice president of State & Local Government Affairs at CHPA.
The legislation passed out of Committee today includes important provisions to accelerate the development and acceptance of innovative, non-animal testing methods for topically applied products, including sunscreens.
Industry calls for clear GRAS/E standards and broader adoption of non-animal testing to advance innovation and safety across all topical OTC products.
“Each brings a wealth of leadership experience, strategic insight, and a deep commitment to consumer health and wellness.”
The congressional caucus will host nonpartisan briefings on supplements, covering science, regulation, and their potential to cut healthcare costs and boost wellness.
The legislation recognizes sunscreen's vital role in skin cancer prevention and seeks to broaden effective sun protection options for U.S. consumers.
While most consumers trust dietary supplements are safe, there is still room to strengthen further confidence in their safety and awareness of how they are regulated.
Dr. Furness joins CHPA after over 25 years at the FDA, where he held several leadership positions.
“These products deliver proven value—every $1 spent on OTC medicines saves over $7 in healthcare costs, totaling $167 billion in annual savings through avoided doctor visits and lower-cost treatment options."
The FDA and HHS have announced plans to phase out petroleum-based synthetic dyes from the national food supply and replace them with natural ingredients.
The awards honor strategic innovation and marketing in OTC medicine, dietary supplements, and OTC medical devices.
“We look forward to working collaboratively with FDA and other stakeholders on this important scientific and regulatory paradigm shift,” says the CHPA.
“It cannot be emphasized enough how vital expanded access to OTC medicines is to public health, and the Rx-to-OTC switch process has delivered safe, effective, and affordable options for decades.”
The Senate confirmed Dr. Makary's nomination by a vote of 56-44.
